Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

Overview

About this study

This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male and female patients 18 years or older
  • Clinical and/or histopathological diagnosis of conventional CSU
  • Unresponsive to oral antihistamine therapy
  • Good general health as confirmed by medical history
  • Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and
  • Patients who read and sign an approved informed consent for this study

Exclusion Criteria:

  • Vulnerable study population
  • Pregnant or nursing women
  • Women planning a pregnancy within the study period
  • Current or previous Xolair use
  • Biopsy proven neutrophilic rich urticaria
  • Known history of adverse reaction to Nucala
  • Severe asthma requiring high-dose inhaled or systemic corticosteroids

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Jason Sluzevich, M.D.

Contact us for the latest status

Contact information:

Jason Sluzevich M.D.

(904)953-7214

Sluzevich.Jason@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20426510

Mayo Clinic Footer